PIPr Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series 1
- Latest Deal Amount
-
$1.5M
- Investors
-
11
PIPr Therapeutics General Information
Description
Developer of a precision therapeutics platform designed to target and block root causes of serious diseases triggered by intestinal inflammation. The company's platform offers therapeutic development capabilities focused on modulating inflammation pathways and disease-driving biological mechanisms, enabling biotechnology and pharmaceutical developers to advance treatments for inflammatory and immune-mediated diseases, improve disease targeting and intervention outcomes.
Contact Information
Website
www.piprtx.comCorporate Office
- 8 Davis Drive Suite 220H
- Durham, NC 27713
- United States
Corporate Office
- 8 Davis Drive Suite 220H
- Durham, NC 27713
- United States
PIPr Therapeutics Timeline
PIPr Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series 1) | 12-Nov-2025 | $1.5M | Completed | Generating Revenue | ||
| 5. Debt - General | 20-Nov-2024 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A2) | 10-Mar-2023 | Completed | Pre-Clinical Trials | |||
| 3. Debt - PPP | 11-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 10-Jun-2019 | $12M | $15M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 06-Feb-2017 | $3M | $3M | Completed | Startup |
PIPr Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 1-A | ||||||||
| Series 1-B | ||||||||
| Series 1-C | 13,427 | $0.000100 | 7% | $1.97 | $1.97 | 1x | $1.97 | 0.18% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PIPr Therapeutics Comparisons
Industry
Financing
Details
PIPr Therapeutics Competitors (12)
One of PIPr Therapeutics’s 12 competitors is Toleranzia, a Private Equity-Backed company based in Gothenburg, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Toleranzia | Private Equity-Backed | Gothenburg, Sweden | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Corbus Pharmaceuticals Holdings | Formerly VC-backed | Norwood, MA | ||||
| Oncorus | Formerly VC-backed | Andover, MA |
PIPr Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PIPr Therapeutics Patents
PIPr Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3232883-A1 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| EP-4405330-A1 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| EP-4405330-A4 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| US-20250320181-A1 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| WO-2023049785-A1 | Small molecule inhibitors of bacterial toxins | Inactive | 24-Sep-2021 | C07C333/04 |
PIPr Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PIPr Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| North Carolina Biotechnology Center | Not-For-Profit Venture Capital | Minority | ||
| AlleyCorp | Venture Capital | Minority | ||
| Biohaven | Corporation | Minority | ||
| Brii Biosciences | Corporation | Minority |
PIPr Therapeutics FAQs
-
When was PIPr Therapeutics founded?
PIPr Therapeutics was founded in 2016.
-
Where is PIPr Therapeutics headquartered?
PIPr Therapeutics is headquartered in Durham, NC.
-
What is the size of PIPr Therapeutics?
PIPr Therapeutics has 7 total employees.
-
What industry is PIPr Therapeutics in?
PIPr Therapeutics’s primary industry is Drug Discovery.
-
Is PIPr Therapeutics a private or public company?
PIPr Therapeutics is a Private company.
-
What is the current valuation of PIPr Therapeutics?
The current valuation of PIPr Therapeutics is .
-
What is PIPr Therapeutics’s current revenue?
The current revenue for PIPr Therapeutics is .
-
How much funding has PIPr Therapeutics raised over time?
PIPr Therapeutics has raised $36.4M.
-
Who are PIPr Therapeutics’s investors?
Alexandria Venture Investments, North Carolina Biotechnology Center, AlleyCorp, Biohaven, and Brii Biosciences are 5 of 11 investors who have invested in PIPr Therapeutics.
-
Who are PIPr Therapeutics’s competitors?
Toleranzia, AnTolRx, Xenetic Biosciences, Corbus Pharmaceuticals Holdings, and Oncorus are some of the 12 competitors of PIPr Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
